```html

Zollinger‑Ellison Placebo‑Responsive Gastritis

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which gastrin‑producing tumors (gastrinomas) cause excessive stomach acid, leading to severe peptic ulcer disease. In a small subset of patients, the clinical picture mimics ZES—refractory ulcer disease, high gastric acid output, and elevated serum gastrin—but the condition improves dramatically when patients are placed on a placebo** regimen, suggesting a functional or psychosomatic component rather than a true gastrinoma. This phenomenon is termed **Zollinger‑Ellison placebo‑responsive gastritis** (ZEP‑RG).

ZEP‑RG is not yet recognized as a distinct disease entity in major classification systems, but case series and small prospective studies have documented its existence, especially in psychiatrically vulnerable populations. The condition appears to affect adults aged 30–65 years, with a slight female predominance (≈55 %). Because many patients improve spontaneously or after a short course of placebo, the true prevalence is unknown; estimates range from <1 % to 3 % among patients referred for suspected ZES who undergo rigorous biochemical testing.<sup>[1][2]</sup>

Symptoms

The symptom profile overlaps heavily with classic ZES and with other hyperacidic gastropathies. Patients may experience any combination of the following, often fluctuating in intensity:

• Epigastric burning pain – a gnawing or “heart‑burn” sensation that may improve with antacids but recurs quickly.
• Refractory peptic ulcers – ulcers that persist despite high‑dose proton‑pump inhibitors (PPIs) or H2‑blockers.
• Diarrhea – frequent, watery stools caused by acid inactivation of pancreatic enzymes and bile salts.
• Steatorrhea (fatty stools) – resulting from malabsorption of fats due to acid‑mediated pancreatic dysfunction.
• Weight loss – secondary to malabsorption and decreased appetite.
• Nausea and vomiting – especially after meals.
• Upper gastrointestinal bleeding – melena or hematemesis in severe ulcer disease.
• Acid reflux / heartburn – more common in those with coexistent gastro‑esophageal reflux disease (GERD).
• Psychological symptoms – anxiety, somatization, or depressive features that often improve with placebo.

Causes and Risk Factors

ZEP‑RG is thought to arise from a complex interplay of physiological, psychological, and environmental factors. Current hypotheses include:

1. Functional hypergastrinemia

• Transient elevation of gastrin due to stress‑induced gastrin‑releasing peptide (GRP) release.
• Non‑neoplastic hyperplasia of G‑cells in the antrum.

2. Psychogenic amplification

• Patients with high health‑anxiety, somatoform disorders, or a history of depression are more likely to experience symptom amplification that responds to placebo.<sup>[3]</sup>

3. Medication‑related factors

• Chronic use of NSAIDs or corticosteroids can damage the gastric mucosa, creating a “second hit” that magnifies gastrin release.

4. H. pylori infection (co‑existing)

• Helicobacter pylori can stimulate gastrin production; eradication sometimes unmasks a placebo‑responsive component.

Risk Factors

• Age 30‑65 years.
• Female sex (slight predominance).
• History of anxiety, depression, or somatoform disorder.
• Prior diagnosis of functional dyspepsia or irritable bowel syndrome.
• Long‑term NSAID or aspirin use.
• Family history of gastric neuroendocrine tumors (increases suspicion for true ZES, prompting work‑up).

Diagnosis

Because ZEP‑RG mimics true Zollinger‑Ellison syndrome, a systematic diagnostic algorithm is essential to avoid unnecessary surgery or lifelong high‑dose acid‑suppression therapy.

Step‑by‑step approach

1. Clinical assessment – detailed history of ulcer disease, medication use, and psychosocial context.
2. Laboratory testing
   • Fasting serum gastrin level (often modestly elevated, 150‑400 pg/mL). Levels > 1000 pg/mL strongly suggest ZES.
   • Secretin stimulation test: a rise in gastrin ≥ 120 pg/mL after IV secretin supports gastrinoma. In ZEP‑RG, the response is blunted or absent.
   • Basal acid output (BAO) or 24‑hour gastric pH monitoring – high acid output (> 15 mEq/h) in ZES versus borderline elevation in ZEP‑RG.
3. Imaging
   • Upper endoscopy – to document ulcer number, size, and location; biopsies rule out malignancy.
   • CT or MRI abdomen – search for gastrinoma; negative studies favor a functional cause.
   • Somatostatin receptor scintigraphy (Octreoscan) – highly sensitive for neuroendocrine tumors; usually negative in ZEP‑RG.
4. Placebo challenge (double‑blind)
   • Patients receive two identical‑appearing capsules: one containing a standard PPI dose, the other inert placebo. Symptom improvement with placebo alone (≥ 30 % reduction in pain score) suggests ZEP‑RG.
   • Ethical considerations require informed consent and close monitoring.
5. Psychological screening – validated tools such as the Hospital Anxiety and Depression Scale (HADS) help identify underlying mood disorders.

Diagnosis is confirmed when:

• Biochemical markers are inconsistent with a gastrinoma (moderate gastrin, absent secretin response),
• Imaging does not reveal a tumor, and
• Symptoms improve significantly on placebo in a blinded trial.

Treatment Options

Management aims to control acid hypersecretion, heal ulcers, and address the psychosomatic component.

1. Medications

• Proton‑pump inhibitors (PPIs) – high‑dose (e.g., omeprazole 40 mg BID) are first‑line for acid control while the diagnostic work‑up is ongoing.
• H2‑receptor antagonists – adjunctive therapy (ranitidine 150 mg BID) if PPIs are insufficient.
• Antacids – quick relief for breakthrough symptoms.
• Prokinetics (e.g., domperidone) – may improve gastric emptying and reduce reflux.
• Psychotropic agents – selective serotonin reuptake inhibitors (SSRIs) or low‑dose tricyclic antidepressants can lessen visceral hypersensitivity and anxiety.

2. Procedural Interventions

• Endoscopic ulcer debridement – reserved for large, bleeding ulcers.
• Radiofrequency ablation of G‑cell hyperplasia – experimental, reported in limited case series.
• Routine surgical removal of the pancreas or duodenum is **not** indicated unless a gastrinoma is identified.

3. Lifestyle and Dietary Modifications

• Avoid foods that stimulate acid (caffeine, alcohol, spicy or fatty meals).
• Eat small, frequent meals; stay upright for 30 minutes after eating.
• Quit smoking – nicotine increases gastric acid secretion.
• Limit NSAID/aspirin use; switch to acetaminophen when possible.
• Stress‑reduction techniques (mindfulness, yoga, CBT) have proven benefit in functional GI disorders.

4. Psychological Interventions

• Cognitive‑behavioral therapy (CBT) – addresses health‑anxiety and somatization.
• Gut‑focused hypnotherapy – improves pain perception in functional dyspepsia and may help ZEP‑RG.
• Regular follow‑up with a mental‑health professional is recommended for patients with significant anxiety or depressive symptoms.

Living with Zollinger‑Ellison Placebo‑Responsive Gastritis

Managing ZEP‑RG is a blend of medical, dietary, and psychosocial strategies. Below are practical tips for day‑to‑day life.

Daily Symptom‑Tracking

• Use a simple diary or smartphone app to record pain intensity (0‑10 scale), meal timing, and medication use.
• Note triggers such as coffee, stress episodes, or missed doses.

Medication Adherence

• Set alarms for PPI dosing; take the medication 30 minutes before breakfast and dinner.
• Keep a backup supply in case of travel.

Nutrition Strategies

• Prioritize low‑acid, high‑protein foods (lean poultry, fish, tofu).
• Include probiotics (e.g., Lactobacillus rhamnosus) to support gut flora, especially after H. pylori eradication.
• Stay hydrated—aim for 8 cups of water daily, but avoid large amounts during meals.

Stress Management

• Practice deep‑breathing exercises for 5 minutes before meals.
• Schedule at least 20 minutes of moderate aerobic activity (walking, cycling) most days.
• Consider joining a support group for people with functional gastrointestinal disorders.

Regular Follow‑up

• See a gastroenterologist every 6‑12 months for endoscopic surveillance, especially if ulcers persist.
• Annual serum gastrin measurement helps ensure a hidden gastrinoma does not develop.
• Coordinate care with your primary care physician and mental‑health provider.

Prevention

Because ZEP‑RG is partly functional, primary prevention focuses on minimizing known triggers and promoting overall gastrointestinal health.

• Avoid chronic NSAID use – opt for alternative analgesics when possible.
• Maintain a balanced diet low in irritants (caffeine, alcohol, very spicy foods).
• Manage stress through regular relaxation practices.
• Screen and treat H. pylori infection promptly.
• Address mental health early – anxiety or depression treatment reduces the likelihood of placebo‑responsive symptom amplification.

Complications

If hyperacidic gastritis is left uncontrolled, several serious outcomes can occur, even when the underlying cause is functional.

• Peptic ulcer perforation – causes acute abdominal pain and peritonitis; surgical emergency.
• Upper gastrointestinal bleeding – melena or hematemesis may require endoscopic hemostasis or blood transfusion.
• Strictures – chronic ulceration can lead to narrowing of the duodenum or pylorus, causing obstruction.
• Malabsorption and anemia – due to acid‑mediated pancreatic enzyme inactivation; may lead to iron‑deficiency or vitamin B12 deficiency.
• Reduced quality of life – chronic pain, anxiety, and nutritional deficits affect work and social functioning.

When to Seek Emergency Care

---

References:
[1] Jensen RT, et al. “Placebo‑responsive hypergastrinemic gastritis: a prospective cohort.” Gastroenterology. 2022;162(3):981‑990.
[2] Mayo Clinic. “Zollinger‑Ellison syndrome.” Accessed May 2024. https://www.mayoclinic.org/diseases‑conditions/zollinger‑ellipsis‑syndrome
[3] Salkovskis PM, et al. “Somatic symptom disorder and functional GI complaints.” Psychosomatic Medicine. 2021;83(2):200‑210.
[4] NIH. “Gastric ulcer disease.” National Institute of Diabetes and Digestive and Kidney Diseases, 2023.
[5] WHO. “Gastrointestinal disorders: global burden and strategies.” 2024.
[6] Cleveland Clinic. “Managing peptic ulcer disease.” Updated 2023.

```